<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0003674'>Oxidative stress</z:mp> has been paid increasing attention to as an important causative factor for <z:e sem="disease" ids="C0011875" disease_type="Disease or Syndrome" abbrv="">diabetic vascular complications</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Among possible various sources, accumulating evidence has indicated that <z:chebi fb="0" ids="13392">NAD(P)H</z:chebi> oxidase may be the most important source for reactive oxygen species production in diabetic vascular tissues </plain></SENT>
<SENT sid="2" pm="."><plain>The mechanisms underlying activation and up-regulation of <z:chebi fb="0" ids="13392">NAD(P)H</z:chebi> oxidase has been supposed to be mediated by high <z:chebi fb="105" ids="17234">glucose</z:chebi>-induced protein kinase C (PKC) activation </plain></SENT>
<SENT sid="3" pm="."><plain>In this review article, activation of local renin-<z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> system induced by chymase activation is also shown to amplify such a PKC-dependent activation of <z:chebi fb="0" ids="13392">NAD(P)H</z:chebi> oxidase </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, human evidence showing the beneficial effect of <z:chebi fb="11" ids="22586">antioxidants</z:chebi> on <z:e sem="disease" ids="C0011875" disease_type="Disease or Syndrome" abbrv="">diabetic vascular complications</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="16990">Bilirubin</z:chebi> has been recognized as a strong endogenous <z:chebi fb="11" ids="22586">antioxidant</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Here markedly lower prevalence of vascular complications is shown in diabetic patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert syndrome</z:e>, a congenital <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, as well as reduced markers of <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Lastly, <z:chebi fb="0" ids="35664">statin</z:chebi>, <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker, chymase inhibitor, <z:chebi fb="0" ids="16990">bilirubin</z:chebi> and <z:chebi fb="0" ids="17033">biliverdin</z:chebi>, PKC Î² isoform inhibitor, and glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 analog, are shown to serve as <z:chebi fb="11" ids="22586">antioxidants</z:chebi> and have some beneficial effect on <z:e sem="disease" ids="C0011875" disease_type="Disease or Syndrome" abbrv="">diabetic vascular complications</z:e>, via inhibiting PKC-<z:chebi fb="0" ids="13392">NAD(P)H</z:chebi> oxidase activation, supporting the notion that this mechanism may be an effective therapeutic target for preventing <z:e sem="disease" ids="C0011875" disease_type="Disease or Syndrome" abbrv="">diabetic vascular complications</z:e> </plain></SENT>
</text></document>